contents page 1
TRANSCRIPT
REVIEWS
FOUNDATION
8 Tailoring chronic pain treatments for the elderly: are we prepared for the challenge?Stephen P. Arneric, Jennifer M.A. Laird, Amy S. Chappell and Jeffrey D. Kennedy
18 Thymoquinone: fi fty years of success in the battle against cancer modelsRegine Schneider-Stock, Isabelle H. Fakhoury, Angela M. Zaki, Chirine O. El-Baba and Hala U. Gali-Muhtasib
KEYNOTE
31 Toward the practical implementation of eye-related bioavailability prediction modelsIvan Pepic, Jasmina Lovric, Biserka Cetina-Cižmek, Stephan Reichl and Jelena Filipovic-Grcic
INFORMATICS
45 Fragment-based error estimation in biomolecular modelingJohn C. Faver and Kenneth M. Merz Jr.
POST SCREEN
51 Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerationsHan Kiat Ho, Angie Hui Ling Yeo, Tse Siang Kang and Boon Tin Chua
63 Human pregnane X receptor: a novel target for anticancer drug developmentVijay Rathod, Sumit Jain, Prajwal Nandekar and Abhay T. Sangamwar
71 Strategies and validation for siRNA-based therapeutics for the reversal of multi-drug resistance in cancerTahereh Fatemian, Iekhsan Othman and Ezharul Hoque Chowdhury
79 Chemistry-enabled drug delivery (prodrugs): recent progress and challengesSophie-Dorothee Clas, Rosa I. Sanchez and Rebecca Nofsinger
88 Biofunctionalisation of electrically conducting polymersCatalina Vallejo-Giraldo, Adriona Kelly and Manus J.P. Biggs
95 Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applicationsHui Wei, Jingjie Mo, Li Tao, Reb J. Russell, Adrienne A. Tymiak, Guodong Chen, Roxana E. Iacob
and John R. Engen
CONTENTS 1
u
January 2014 Volume 19 Number 1 pp. 1 – 104
Cover StoryThe leading story of this issue of Drug Discovery Today by Stephen P. Arneric, Jennifer M.A. Laird, Amy S. Chappell and Jeffrey D. Kennedy entitled “Tailoring Chronic Pain Treatments for the Elderly: Are We Prepared for the Challenge?” details how Chronic pain is increasingly recognized as a disease and accounts for substantial suffering and disability world-wide. It questions whether a shift in the drug discovery paradigm will be necessary to improve effi cacy, side-effects or positively impact quality of life (QoL) in the elderly with chronic pain? This short review further highlights a number of potential pitfalls, that should be considered when delivering valued pain relief medicines tailored for the elderly.
ScienceDirect